Sign In
Buy MTSR
$70.50
+0 (+0%)
At Close: Feb 12, 2026
Mizuho's Holtz talks what is behind Novo's bid for Metsera
06:20pm, Thursday, 30'th Oct 2025
Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat.
Novo: Risks Revisited And Potential Metsera Deal
05:23pm, Thursday, 30'th Oct 2025
Novo Nordisk A/S remains a Buy ahead of Q3 2025 earnings, but I reassess key risks and competitive pressures. NVO faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly,
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
01:13pm, Thursday, 30'th Oct 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
12:40pm, Thursday, 30'th Oct 2025
Metsera has become the obesity drug market's hottest ticket.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
11:39am, Thursday, 30'th Oct 2025
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal
09:52am, Thursday, 30'th Oct 2025
Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
07:11am, Thursday, 30'th Oct 2025
Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Metsera Receives Unsolicited Proposal from Novo Nordisk
07:07am, Thursday, 30'th Oct 2025
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and P
Pfizer Addresses Proposal for Metsera
06:57am, Thursday, 30'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a co
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
06:23am, Thursday, 30'th Oct 2025
Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.
Novo Nordisk gatecrashes Pfizer's takeover of obesity rival Metsera
06:06am, Thursday, 30'th Oct 2025
Novo Nordisk (NYSE:NVO) has attempted to gatecrash Pfizer Inc (NYSE:PFE, ETR:PFE)deal to buy obesity drug developer Metsera Inc (NASDAQ:MTSR), with an unsolicited offer of $6.5 billion, rising to a
Novo Nordisk makes unsolicited offer for Metsera
05:57am, Thursday, 30'th Oct 2025
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera.
Novo Nordisk submits proposal to acquire Metsera, Inc.
05:49am, Thursday, 30'th Oct 2025
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports
05:47am, Thursday, 30'th Oct 2025
Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on
3 Investable Laggards In An Overbought Market
05:13pm, Tuesday, 28'th Oct 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo
